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Abstract
In type 1 diabetes, pancreatic beta cells are destroyed by chronic autoimmune responses. The disease develops in genetically
susceptible individuals, but a role for environmental factors has been postulated. Viral infections have long been considered as
candidates for environmental triggers but, given the lack of evidence for an acute, widespread, cytopathic effect in the pancreas in
type 1 diabetes or for a closely related temporal association of diabetes onset with such infections, a role for viruses in type 1
diabetes remains unproven. Moreover, viruses have rarely been isolated from the pancreas of individuals with type 1 diabetes,
mainly (but not solely) due to the inaccessibility of the organ. Here, we review past and recent literature to evaluate the proposals
that chronic, recurrent and, possibly, persistent enteroviral infections occur in pancreatic beta cells in type 1 diabetes. We also
explore whether these infections may be sustained by different virus strains over time and whether multiple viral hits can occur
during the natural history of type 1 diabetes. We emphasise that only a minority of beta cells appear to be infected at any given
time and that enteroviruses may become replication defective, which could explain why they have been isolated from the
pancreas only rarely. We argue that enteroviral infection of beta cells largely depends on the host innate and adaptive immune
responses, including innate responses mounted by beta cells. Thus, we propose that viruses could play a role in type 1 diabetes on
multiple levels, including in the triggering and chronic stimulation of autoimmunity and in the generation of inflammation and the
promotion of beta cell dysfunction and stress, each of which might then contribute to autoimmunity, as part of a vicious circle. We
conclude that studies into the effects of vaccinations and/or antiviral drugs (some of which are currently on-going) is the only
means by which the role of viruses in type 1 diabetes can be finally proven or disproven.
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Introduction
A role for infectious agents in type 1 diabetes was proposed in
the 1920s, following reports of diabetes after parotitis [1],
suggesting viruses with affinity for the pancreas existed.
Since then, numerous studies have reported associations be-
tween type 1 diabetes and a variety of viruses, including en-
teroviruses, herpesviruses, parechoviruses, rotaviruses and
retroviruses [2]. Of these, the most extensive studies and ro-
bust associations have been observed with enteroviruses, both
clinically and experimentally. Nonetheless, a role for viruses
in type 1 diabetes is still considered unproven. Here, we re-
view the evidence and consider how viruses might contribute
to type 1 diabetes in multiple, perhaps unconventional, ways.
From this evidence, we propose that the development and
clinical evaluation of an enterovirus vaccine for preventing
type 1 diabetes is scientifically justified.
Epidemiological and genetic studies implicate
enteroviruses in type 1 diabetes
In 1969, seasonal variation in type 1 diabetes diagnoses was
correlated with the prevalence of the enterovirus coxsackievirus
B (CVB)4 [3]. In 1973, individuals with newly diagnosed type
1 diabetes were found to have neutralising antibodies to CVB4
more frequently than control individuals [4]. Since then, many
other epidemiological and clinical investigations have been
conducted in birth cohorts of children at genetic risk of type 1
diabetes to address the role of enteroviruses in the initiation and
acceleration of islet autoimmunity [5–8]. The results have not
always been concordant, in part due to methodological limita-
tions and inadequacies of sampling timing and frequency; how-
ever, the weight of the evidence, derived from multiple coun-
tries, clearly supports an association between enteroviruses and
type 1 diabetes [9, 10]. This is supported by studies reporting
that: (1) maternal viral infection in pregnancy, including entero-
viral, is linked to type 1 diabetes risk in the offspring, as
confirmed by a meta-analysis of ten studies (2992 participants,
both mothers and offspring) [11]; (2) detection of enteroviruses
in stools [12] and circulating antivirus neutralising antibodies
[13] precedes the appearance of islet autoantibodies by several
months in children at increased genetic risk for type 1 diabetes;
and (3) faster progression to type 1 diabetes occurs in
autoantibody-positive children with enterovirus RNA in their
blood [6].
Genetic studies imply that innate responses to viruses are
controlled by alleles associated with risk of type 1 diabetes.
The IFIH1 gene [14] encodes melanoma differentiation-
associated protein 5 (MDA5), a helicase that recognises
double-stranded RNA (dsRNA) generated during enterovirus
replication, and promotes interferon, NF-κB and cytokine re-
sponses. In the presence of IFIH1 predisposing alleles, the
interferon response to viral infection of pancreatic islets is
altered [15]. Interferons upregulate HLA class I molecules
and this is a key feature of beta cell pathology in type 1 dia-
betes [16], which increases the cell's potential to present self-
antigens and trigger autommunity [17]. Other genes that have
an impact on viral infections, such as PTPN2 and TYK2, are
linked to the genetic risk of type 1 diabetes. These genes
promote endoplasmic reticulum (ER) stress, leading to im-
paired beta cell function and survival [18, 19]. The link be-
tween environmental factors and genetic predisposition sup-
ports the concept that genetically determined host responses to
enteroviruses affect the outcome of infection and the develop-
ment of type 1 diabetes. Overall, epidemiological evidence
supports an association between enterovirus infection and islet
autoimmunity and type 1 diabetes, whilst genetic data link
disease with enteroviral infections and host responses to the
virus.
Pancreas pathology reveals low-grade,
chronic enterovirus infections
Access to the pancreas at or soon after diagnosis of type 1
diabetes is rare, and so are reports that viruses can be isolated
from the pancreas at this stage. In 1979, CVB4 was isolated
from the pancreas of a child with recently diagnosed type 1
diabetes; the virus infected mice and caused viral protein ex-
pression in beta cells, islet inflammation, beta cell necrosis
and hyperglycaemia [20]. In 2007, CVB4 infection was re-
ported in the pancreas of three of six individuals with type 1
diabetes and, following extraction, the virus infected beta cells
from pancreatic donors without diabetes [21]. However, acute,
lytic, widespread viral infections have not been reported in the
pancreas in type 1 diabetes (except in rare cases of the atypical
fulminant type 1 diabetes [22]), regardless of whether samples
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were from the Exeter Archival Diabetes Biobank (EADB;
autopsy pancreases) [23], the Network for Pancreatic Organ
Donors with Diabetes (nPOD) [24] or the Diabetes Virus
Detection Study (DiViD) [25], all of which include pancreases
from individuals with newly diagnosed type 1 diabetes.
In the DiViD study, pancreas biopsies were obtained from
six adults with recent-onset type 1 diabetes [26]. Using RT-
PCR and sequencing, enterovirus was detected in four of these
donors but in none of six non-diabetic control donors [25]. In
contrast, using combined virus culture with PCR, enterovirus
genome was detected in all six DiViD donors with type 1
diabetes and, when isolated, the viruses from these donors
infected permissible cell cultures and were propagated be-
tween cultures [27]. The enterovirus capsid protein viral pro-
tein 1 (VP1) and marked HLA class I hyperexpression were
detected in islets from all type 1 diabetes DiViD donors, com-
pared with only n = 2 and n = 1 of the nine control donors
tested, respectively [25].
Consistently across the EADB, DiViD and nPOD cohorts,
VP1 is detected in a small proportion of insulin-positive, re-
sidual beta cells; within VP1+ cases, between 6.9% and 28.6%
of residual insulin-containing islets display VP1+ cells and,
within those, between 1.8% and 5.5% of the endocrine cells
are VP1+ (Table 1) [21, 23–25]. This is especially true in islets
with insulitis and/or hyperexpressing HLA class I molecules
[16, 28] and has been found across a wide age range [23, 24].
In studies of nPOD donors, unbiased proteomic analysis has
verified the presence of viral proteins, including the VP1 epi-
tope (J. Nyalwidhe and J. Nadler, Eastern Virginia Medical
School, Norfolk, VA, USA, personal communication). Studies
of nPOD donors demonstrate that VP1 can be detected for
about 10 years after diagnosis. Overall, the findings are con-
sistent with the notion that low-grade, recurrent or chronic,
persistent infections affect the pancreas in type 1 diabetes
[29]. Conversely, the data do not support widespread acute
infection and direct cytopathic effects on infected cells in type
1 diabetes.
Beta cells can sustain chronic enterovirus
infections
Enteroviruses typically cause acute infectious diseases, dom-
inated by poliomyelitis, childhood hand, foot and mouth dis-
ease, aseptic meningitis and acute myocarditis. However, en-
teroviruses can persist in certain tissues after the acute phase,
as observed in the heart in myocarditis [30] and mouse
pancreases [31]. Persistence is ascribed to deletion of up to
50 nucleotides from the 5′ end of the virus genome [31, 32],
which reduces replication and pathogenic potential. The virus
becomes non-lytic and persists for months at low levels; in
beta cells, this may lead to altered gene expression, ER stress
and toxicity through continued production of viral proteases
that regulate host translation and transcription [33]. VP1+ beta
cells show decreased insulin content and marked upregulation
of the dsRNA sensor protein kinase R (PKR) [24]. These cells
undergo translational arrest in response to PKR activation,
with loss of the anti-apoptotic protein myeloid cell leukemia
1 (Mcl-1) [34]. Islet cells from individuals with newly diag-
nosed type 1 diabetes show increased expression of interferon
response genes and the transcription factor signal transducer
and activator of transcription 1 (STAT1), which is associated
with hyperexpression of HLA class I molecules, demonstrated
both at the protein and RNA level [16]. Once again, the impact
of enteroviruses in diabetes is not simply explained by the
infection per se, but rather derives from host–virus interac-
tions, which can be chronic. Thus, it is important to consider
the impact of viral infections in the context of the target tissue
and host responses and the fact that available data about the
Table 1 Comparison of VP1 sta-
tus in three pancreas biobank co-
horts (EADB, nPOD and DiViD)
Variable EADB
[23, 24]
nPOD
[24]
DiViD
[25]
Control/T1D donors, n 119/72 12/17 9/6
Age of T1D donors, mean years ± SEM 12.7 ± 1.1 25.7 ± 2.9 28.8 ± 2.1
VP1+ control donors, n (%) 12 (10) 1 (8) 2 (22)
VP1+ T1D donors with residual ICIs, n (%) 44 (61) 8 (80)a 6 (100)
No. of T1D islets with VP1+ cells/total no. of
residual ICIs, (%)
77/374 (20.6) 65/227 (28.6) 42/612 (6.9)
VP1+ ECs in VP1+ T1D ICIsb, % ± SEM PM: 1.76 ± 0.32
OD: 5.10 ± 0.87
OD: 5.52 ± 0.90 ND
aNo residual insulin-containing islets in n = 7
b Source: [23]
EC, endocrine cell; ICI, insulin-containing islets; ND, no data; OD, organ donor; PM, post-mortem donor; T1D,
type 1 diabetes
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role of enteroviruses in type 1 diabetes are not consistent with
the conventional concept of an acute, cytopathic infection.
The problem of linking common or slowly
developing chronic infections with disease:
parallels between diabetes and cancer
The difficulties associated with attempts to demonstrate an
association of viruses with type 1 diabetes parallels the prob-
lems encountered when establishing causal relationships be-
tween viruses and cancer. Examples include human papillo-
mavirus (linked with cervical or throat cancer) and hepatitis B
and C viruses (linked with hepatocellular carcinoma). Proof of
viral causality for these cancers was challenging because of
virological and epidemiological issues, which similarly ham-
per the acceptance of a viral role in type 1 diabetes today. The
first issue is that enterovirus infections are common in the
population and have a much higher incidence than type 1
diabetes. Moreover, only certain serotypes may trigger disease
[9]. Importantly, beta cells express the receptor for these sero-
types in the secretory granule membrane where it may pro-
mote infection by facilitating the uptake of virus into the cell
during insulin secretion [35]. Second, there is typically a long
incubation period between the initial viral infection and dia-
betes symptoms, coupled with complex processes leading
from infection to disease. Third, the initial infection may be
asymptomatic, preventing firm establishment of the time of
infection. While a high viral load is reported in virus-
associated cancers, so far there has been no evidence of acute,
severe enterovirus infections affecting the pancreas (or other
organs) relevant to type 1 diabetes, including in studies of
pancreas autopsies and biopsies from donors with new-onset
diabetes. This possibility cannot be formally excluded because
short-lived, acute infections may not be easily demonstrated in
the pancreas for obvious reasons of timing and access; how-
ever, massive viral cytotoxicity has not been noted in beta
cells. Fourth, variation of individual hosts will play a critical
role in disease development; this may arise from variation in
genes that modulate adaptive and innate immune responses
(i.e. HLA alleles, IFIH1), age when infection occurs, prior
immunity and the status of the immune system (Fig. 1).
Type 1 diabetes (like cancers) results from a multistage
process in which viruses may influence the host immune sys-
tem, stress responses and other molecular events in both target
cells and cells of the immune system. The mechanisms lead-
ing to type 1 diabetes occur in the pancreas, involve pancreatic
cells and cells of both the adaptive and innate immune sys-
tems, and are difficult to model experimentally. A major dif-
ference between cancer and type 1 diabetes is the association
with HLA in the latter. The observation that the first appearing
autoantibodies in type 1 diabetes are related to HLA-DR4-
DQ8 and to prior enterovirus infections [36] suggest that
viruses may be involved in triggering beta cell autoimmunity.
Thus, with some important differences as compared with can-
cer, the association of viral infections with type 1 diabetes
needs to be evaluated in the context of a complex disease with
multiple pathogenic mechanisms, some of which remain to be
unveiled.
Emerging evidence for multiple viral hits
by multiple virus strains
In one DiViD type 1 diabetes donor, one enterovirus strain
was detected in the pancreas, whilst a different one was found
in peripheral blood mononuclear cell (PBMCs), stool and du-
odenum. This is consistent with a low-grade persistent infec-
tion in the pancreas (residing from the prediabetic period) plus
an acute systemic infection at diagnosis (K. Dahl-Jørgensen,
unpublished results). In nPOD type 1 diabetes donors, using
PCR, multiple enteroviruses were detected in the pancreas of
individual donors (H. Hyöty and R. Lloyd, unpublished re-
sults), suggesting that infections with more than one enterovi-
rus can co-exist. Enterovirus infection of the pancreas may
occur multiple times in an individual’s life, possibly sustained
by multiple serotypes. Enterovirus infection with a given se-
rotype induces neutralising antibodies that do not afford cross-
protection against different serotypes. Even in the presence of
neutralising antibodies, a second infectionwith the same strain
may not be prevented; depending on the titres of neutralising
antibodies, the second infection may lead to persistence and
chronic tissue damage [37]. It is also unclear whether all or
only some virus infections in the pancreas in type 1 diabetes
are relevant to disease onset and its progression. Moreover,
other viruses and the gut microbiome may modulate enterovi-
rus infections (and the ensuing immune responses); it is pos-
sible that an altered or permissive microbiome or impaired
intestinal barrier facilitate infection by enteroviruses [38].
All of the above suggest the hypothesis that, rather than being
caused by a single, acute infection, multiple viruses (not just
enteroviruses) and other environmental factors may provide
multiple ‘hits’ that, over time, promote type 1 diabetes.
How viral infections might contribute
to the pathogenesis of type 1 diabetes
Viruses may trigger islet autoimmunity, potentially via molec-
ular mimicry, inflammation, ER stress and, ultimately, host
responses, such as bystander activation or suppression of T
cells, which are detrimental to beta cell function and survival
(Fig. 1). In terms of T cell and autoantibody responses, studies
have reported cross-reactivity between islet cell autoantigens
and certain viral proteins [39], yet there is no proof that cross-
reactivity triggers islet autoimmunity. On the other hand, at-
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risk children with insulin autoantibodies have reduced ability
to produce antibodies to VP1, which could facilitate enterovi-
rus infection and persistence [7]. In addition, virus-induced
inflammation and ER stress cause beta cell dysfunction and
protein misfolding, which may lead to abnormal presentation
of autoantigens [40–42]. Cytokine-induced ER stress en-
hances beta cell release of exosomes loaded with autoantigens
and immuno-stimulatory chaperones, which are taken-up by
antigen presenting cells (APCs) [43].
Viruses may also accelerate disease onset in genetically
susceptible individuals; for example, in the Diabetes and
Autoimmunity Study in the Young (DAISY), there was faster
disease progression in autoantibody-positive individuals who
encountered an enterovirus, as indicated by virus RNA in the
blood, than those who had a negative serum enteroviral RNA
test [6]. Similar observations were made in NOD mice infect-
ed with CVBs close to disease onset [44–46]. A prerequisite
for faster disease onset in the NOD mouse model is the
presence of a critical mass of autoreactive T cells within the
islets [44, 47], which may undergo bystander activation [48].
Multiple infections may, therefore, represent iterative trig-
gers for chronic islet autoimmunity, with diabetes symptoms
becomingmanifest when sufficient beta cells have been lost or
have become dysfunctional [49]. In support of this, CVB4
caused beta cell dysfunction in islet grafts when human islets
were transplanted into nude mice [50].
The adaptive immune responses to enteroviruses likely play
a larger role in type 1 diabetes than is currently recognised.
Insulitis (predominantly involving CD8+ T cells) and
hyperexpression of HLA class I molecules in islet cells are
defining features of the pancreas pathology in type 1 diabetes
[16, 49] and correlate with markers of viral infection in beta
cells (VP1) [16]. The immune system may launch an immune
response against viral epitopes on infected beta cells, leading to
beta cell destruction regardless of whether these responses are
cross-reactive with autoantigens.
Acute
infection of
beta cells  
Persistent and/or recurrent infection
Lysis and release of 
beta cell antigens; 
'cytokine storm' in 
islets; appearance of 
islet autoantibodies
Make beta cells 
more visible to 
autoreactive 
T cells
Sensitise beta cells to 
cell death induced by 
cytokines, high 
glucose, fatty acids
Induction of beta cell 
stress and islet antigen 
modifications; beta cell 
dysfunction and reduced 
insulin secretion
Prospective 
cohort studies; 
islet damage in 
fatal infections
↑ HLA Class l;
↑ chemokines, 
IFN signature
↓ Mcl1 in infected  
beta cells
↑ ER stress markers; 
generation of 
neoantigens and/or 
hybrid peptides
Predominates in early childhood
Age-related weakness in antiviral defence
Wide viral spread 
↑ Autoimmunity 
Predominates in teenage years and beyond
↑ Beta cell dysfunction
↑ Autoimmunity
Impact of virus on beta cell survival and function
Process
Mechanism
Evidence
Susceptibility
Fig. 1 Mechanisms by which viruses may impact beta cell survival/
function and contribute to type 1 diabetes pathogenesis. Evidence for
each of the different proposed mechanisms is presented. Genetic sus-
ceptibility to type 1 diabetes could contribute to outcome, with spe-
cific disease-associated SNPs influencing which of the viral impact
mechanisms predominate in a given individual. Furthermore, there is
mounting evidence that pathways could differ depending on age at
type 1 diabetes onset; although each of the pathways can occur at any
age, there is evidence that autoimmunity is more pronounced in in-
dividuals with a younger age at onset, whilst beta cell dysfunction is
greater in individuals who are older at onset
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The relationship between beta cell destruction and antiviral
immune responses is essentially unknown. A fascinating hy-
pothesis is that viruses and infected beta cells may survive if
the infected cells present viral epitopes that are cross-reactive
with beta cell antigens; while cross-reactivity is traditionally
considered a trigger, immune responses to cross-reactive epi-
topes could be regulated and, thus, not highly pathogenic,
which would allow infected cells to survive and the virus to
persist. So far, a small case−control study identified eight
CVB3 epitopes that are presented by HLA-A*0201, but did
not show an association of T cell responses with type 1 dia-
betes [51]. If immunisation with an enterovirus vaccine were
to induce a CD8+ T cell response, it would be important to
assess potential cross-reactivity with islet autoantigens.
However, accelerated disease was not observed in NOD mice
receiving a monovalent CVB vaccine [46].
Overall, the characterisation of cellular immune responses
to enteroviruses in type 1 diabetes, and the relationship of such
responses with autoimmune responses, remains a major area
of investigation, which could yield critical information about
the mechanisms by which enteroviruses contribute to patho-
genesis of the disease.
Rationale for the development of a vaccine
Vaccines would be useful tools to obtain proof of causality
between type 1 diabetes and enteroviruses. Effective and safe
vaccines have been developed against polioviruses and en-
terovirus 71, but there are no vaccines available for the entero-
viruses linked to type 1 diabetes. Recent preclinical studies
provided proof-of-concept that a CVB vaccine prevents viral
infection and diabetes induction in mice harbouring beta cells
genetically permissive to CVB infection [52]. It is critical to
determine which virus serotypes are associated with type 1
diabetes in different geographical regions over various pe-
riods. Existing information is guiding the development of a
polyvalent vaccine directed against CVB serotypes.
Additional information is expected from on-going efforts in
the Environmental Determinants of Diabetes in the Young
(TEDDY) study (conducted in the USA and Europe) and the
Type 1 Diabetes Prediction and Prevention (DIPP) studies (in
Finland), and from the analysis of pancreas pathology.
An enterovirus vaccine may be effective for primary and
secondary prevention of type 1 diabetes, by halting the trig-
gering of autoimmunity and blocking the onset of immune-
mediated beta cell dysfunction and death that follow autoan-
tibody conversion in presymptomatic (stage 1) type 1 diabetes
[53] (Fig. 2). Mechanisms of secondary prevention with an
enterovirus vaccine could include: (1) prevention of consecu-
tive islet infections; (2) prevention of a systemic infection that
either reactivates immune memory resulting in an islet-
targeted immune response or increases the circulating
cytokines and inflammation that generate a relapse or aug-
mentation of islet autoimmunity; and/or (3) limitation of an
intestinal enterovirus infection, which might otherwise accel-
erate the onset of symptomatic disease by altering intestinal
permeability. Avaccine against enteroviruses does not directly
address the potential contribution of other viruses to type 1
diabetes onset and progression, yet it is a pragmatic choice
based on the more extensive association of enteroviruses with
islet autoimmunity and type 1 diabetes.
A potential alternative to vaccination, testable in secondary
and tertiary (new-onset; Fig. 2) prevention trials, is treatment
with antiviral drugs to eliminate an established chronic infec-
tion of the pancreas. One such clinical trial (Diabetes Virus
Detection and Intervention Trial [DiViDInt], launched in
2018, will enrol individuals with newly diagnosed type 1 di-
abetes to a randomised, placebo-controlled double-blinded tri-
al to test a combination of two antiviral drugs (pleconaril and
ribavirin). Antivirals were effective in vitro in pancreatic cell
lines with persistent enterovirus infections [54]. We have re-
cently confirmed this using a wider panel of antiviral drugs
(H. Hyöty et al, unpublished results). Antivirals are effective
in other chronic infections, such as hepatitis B and C [55, 56].
The endpoint of this study will be preservation of beta cell
function; viral markers also may be explored in stools, blood
and saliva [57] but it is presently not known that these would
reflect changes in pancreatic infections. Based on the evidence
discussed so far, both antivirals and vaccination strategies
could play a key role in understanding the role of enterovi-
ruses in type 1 diabetes and could impact on disease risk and
clinical course.
Cost-effectiveness of viral vaccines in type 1
diabetes
The commercial viability of a viral vaccine for therapy of type
1 diabetes needs to be formally evaluated based on its efficacy
in target populations and the overall risk and lifetime cost of
the disease. In addition to the rising disease incidence, the cost
of treatment for stage 3, symptomatic clinical disease (e.g.
insulin, pumps, glucose monitors) is increasing. A vaccine
could reduce other enterovirus comorbidities (e.g. aseptic
meningitis, myocarditis or hand, foot and mouth disease),
most of which are more prevalent than type 1 diabetes.
Persistent enterovirus infection and antiviral tissue responses
also been detected in thyroid tissue from individuals with have
newly diagnosed Graves’ disease [58], Hashimoto’s thyroid-
itis [59], and in those with pericarditis and myocarditis [30].
Thus, it may be possible to include other health outcomes in
vaccination protocols, thereby increasing cost-effectiveness.
Moreover, individuals with type 1 diabetes may suffer from
comorbid coeliac disease and other autoimmune diseases [60,
61], which could conceivably be alleviated by enterovirus
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vaccination. Although initial enteroviral vaccine trials will
probably target infants with high-to-moderate risk of type 1
diabetes based on HLA genotype, the most cost-effective ap-
proach would be universal infant immunisation with the dou-
ble benefit of avoiding the cost of neonatal HLA genotyping
while preventing enterovirus diseases in a greater number of
children.
Conclusions
In recent years, a combination of epidemiological, histological
and animal studies has strengthened the evidence for a role for
enteroviruses in type 1 diabetes. Because of the limitations of
epidemiology studies, the long incubation period between the
onset of islet autoimmunity and symptomatic type 1 diabetes,
and the complexity of a potential role of both acute and chron-
ic enterovirus infection in the disease pathogenesis, definitive
proof of a causal role for enteroviruses in type 1 diabetes
requires further investigation. Specifically, it should be dem-
onstrated that prevention of enteroviral infections prevents
type 1 diabetes. An enteroviral vaccine, and/or antivirals,
can help to fulfil this goal. The recent announcement that a
CVB vaccine will be developed for type 1 diabetes therapy
substantiates this claim [62]. If this vaccine can prevent type 1
diabetes development, even in a proportion of cases, this
would dramatically impact the health and economic burden
of the disease. Efficacy may be tested initially in shorter trials
using surrogate endpoints, such as progression to stage 1 dis-
ease, or progression from stage 1 to 2 or stage 2 to 3. The cost-
effectiveness and early prognostic biomarkers for type 1 dia-
betes remain understudied and will play a critical role in de-
termining the utility of viral vaccines. Only a rigorous evalu-
ation of the outcomes of vaccination and antiviral therapies
can provide the ultimate proof that viruses are causally asso-
ciated with type 1 diabetes and could help address the mech-
anisms by which viruses play a role in development of the
disease.
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